LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

Search

Verve Therapeutics Inc

Cerrado

6.19 8.22

Resumen

Variación precio

24h

Actual

Mínimo

6.16

Máximo

6.54

Métricas clave

By Trading Economics

Ingresos

19M

-31M

Ventas

20M

33M

BPA

-0.35

Margen de beneficios

-94.108

Empleados

274

EBITDA

18M

-37M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 Meses

+318.85% upside

Dividendos

By Dow Jones

Próximas Ganancias

6 ago 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

40M

427M

Apertura anterior

-2.03

Cierre anterior

6.19

Puntuación técnica

By Trading Central

Confianza

Strong Bearish Evidence

Verve Therapeutics Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

6 jun 2025, 14:31 UTC

Ganancias

New York State Retirement Fund Posts 5.84% Annual Investment Return

6 jun 2025, 20:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

6 jun 2025, 20:50 UTC

Charlas de Mercado

Auto & Transport Roundup: Market Talk

6 jun 2025, 20:33 UTC

Ganancias

These Stocks Moved the Most Today: Tesla, DJT, Broadcom, Circle, Lululemon, Docusign, Quanex, Braze, and More -- Barrons.com

6 jun 2025, 19:36 UTC

Charlas de Mercado

Oil Futures Post Solid Weekly Gains -- Market Talk

6 jun 2025, 19:28 UTC

Charlas de Mercado

U.S. Natural Gas Futures Rise on Demand Expectations -- Market Talk

6 jun 2025, 18:46 UTC

Charlas de Mercado

Gold Faced With Tariff Uncertainty Offset by ETF Withdrawals -- Market Talk

6 jun 2025, 18:02 UTC

Charlas de Mercado

U.S. Oil Rig Count Continues to Decline -- Market Talk

6 jun 2025, 16:35 UTC

Ganancias

These Stocks Are Moving the Most Today: Tesla, DJT, Broadcom, Circle, Lululemon, Docusign, Quanex, Braze, and More -- Barrons.com

6 jun 2025, 16:34 UTC

Ganancias

These Stocks Are Moving the Most Today: Tesla, DJT, Broadcom, Circle, Lululemon, Docusign, Quanex, Braze, and More -- Barrons.com

6 jun 2025, 16:21 UTC

Charlas de Mercado

Canadian Unemployment Set to Continue Feel Trade War Pressures -- Market Talk

6 jun 2025, 16:20 UTC

Charlas de Mercado

Auto & Transport Roundup: Market Talk

6 jun 2025, 16:20 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

6 jun 2025, 16:20 UTC

Charlas de Mercado

Health Care Roundup: Market Talk

6 jun 2025, 16:15 UTC

Charlas de Mercado

Global Commodities Roundup: Market Talk

6 jun 2025, 16:07 UTC

Charlas de Mercado

Market Talk Roundup: Latest on U.S. Politics

6 jun 2025, 16:07 UTC

Charlas de Mercado

Base Metal Prices Slide But Copper Set to End Week Higher -- Market Talk

6 jun 2025, 15:53 UTC

Charlas de Mercado

Mexican Inflation Seen Rising in May -- Market Talk

6 jun 2025, 15:36 UTC

Charlas de Mercado

Dollar's Boost From U.S. Jobs Data Could Be Limited -- Market Talk

6 jun 2025, 15:36 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

6 jun 2025, 15:33 UTC

Charlas de Mercado

Gold Futures Slide After Jobs Data Surprises to Upside -- Market Talk

6 jun 2025, 15:16 UTC

Charlas de Mercado

Tesla Showing Signs of Weakness in Key Regions -- Market Talk

6 jun 2025, 15:05 UTC

Charlas de Mercado

Silver at its Highest In Nearly 15 Years -- Market Talk

6 jun 2025, 14:35 UTC

Charlas de Mercado

Weakening Canadian Job Market Seen Keeping BoC in Easing Mode -- Market Talk

6 jun 2025, 14:28 UTC

Charlas de Mercado

Bitcoin Rises After Above-Forecast U.S. Jobs Data -- Market Talk

6 jun 2025, 14:28 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

6 jun 2025, 14:28 UTC

Charlas de Mercado

Canada's Job Market Weakens But Not Seen Collapsing -- Market Talk

6 jun 2025, 14:15 UTC

Charlas de Mercado

Oil Rises on U.S.-China Talks Optimism -- Market Talk

6 jun 2025, 14:12 UTC

Ganancias

Palantir and Super Micro Computer Stocks Rise as Broadcom Posts Strong AI Revenue -- Barrons.com

6 jun 2025, 14:09 UTC

Ganancias

Broadcom, the $1 Trillion Stock You Shouldn't Ignore, Makes AI Investment Case -- Barrons.com

Comparación entre iguales

Cambio de precio

Verve Therapeutics Inc previsión

Precio Objetivo

By TipRanks

318.85% repunte

Estimación a 12 Meses

Media 24 USD  318.85%

Máximo 39 USD

Mínimo 15 USD

De acuerdo con 10 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Verve Therapeutics Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

10 ratings

9

Comprar

1

Mantener

0

Vender

Puntuación técnica

By Trading Central

4.1501 / 5.16Soporte y Resistencia

Corto Plazo

Strong Bearish Evidence

Medio plazo

Very Strong Bearish Evidence

Largo Plazo

Bearish Evidence

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Verve Therapeutics Inc

Verve Therapeutics, Inc., a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH. It engages in the development of ANGPTL3 program to permanently turn off the ANGPTL3 gene in the liver. It has a collaboration and license agreement with Beam Therapeutics Inc.; a development and option agreement with Acuitas Therapeutics, Inc.; and a Cas9 license agreement with The Broad Institute and the President and Fellows of Harvard College. The company was formerly known as Endcadia, Inc. and changed its name to Verve Therapeutics, Inc. in January 2019. Verve Therapeutics, Inc. was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.